EU RISK ASSESSMENT ON ADB-CHMINACA AS NEW PSYCHOACTIVE DRUG

Also on 14^th May, the European Monitoring Centre for Drugs and Drug Addiction published a report that presents the data and findings of the risk assessment on N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA) carried out by the extended Scientific Committee of the EMCDDA in November 2017.  On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 14^th May, the Council decided that ADB-CHMINACA should be subject to control measures across the Member States as a New Psychoactive Substance (NPS).  N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, also known as ADB-CHMINACA and MAB-CHMINACA, is a synthetic cannabinoid receptor agonist (synthetic cannabinoid).

http://www.emcdda.europa.eu/system/files/publications/8619/Risk_assessment_ADB_CHMINACA.pdf

Author: raytodd2017

Chartered Legal Executive and former senior manager with Isle of Man Customs and Excise, where I was (amongst other things) Sanctions Officer (for UN/EU sanctions), Export Licensing Officer and Manager of the Legal-Library & Collectorate Support Section View all posts by raytodd2017